Biodefense Market Size By Product (Anthrax, Small Pox, Botulism, Radiation/ Nuclear), Industry Analysis Report, Regional Outlook (U.S., Canada, U.K, Germany, China, Japan, Mexico, Brazil, South Africa), Application Potential, Price Trends, Competitive Market Share & Forecast, 2016 – 2024
Published Date: August 2016 | 82 Pages | Report ID: GMI714 Report Format: PDF
Biodefense Market size was USD 9.7 billion in 2015, with 6.9% CAGR estimation from 2016 to 2024.
U.S. Biodefense Market Size, by Product, 2012 - 2024 (USD Million)
Increasing threat of bioterrorism and presence of favorable government initiatives against bio-terrorism are significant factors that will drive the global market in the coming years. Several government laws such as Project Bioshield provides countries with countermeasures against any chemical, biological, radiological or nuclear (CBRN) attack. Regulatory bodies such as Biomedical Advanced Research and Development Authority (BARDA), National Institute of Allergy and Infectious Diseases (NIAID) encourage funding for development of therapeutic products.
Project BioShield ensures the availability of ‘next generation’ medical countermeasures against anthrax, smallpox and other CBRN agents. The primary objectives of the project include creation of funding authority to develop next generation countermeasures, design new and speedy R&D programs, and development of a speedy authorization body like FDA to permit effective use of treatments in emergency.
Introduction of “Emergency Use Authorization (EUA) of medical products” explains the policies of the Food and Drug Administration stated under section 564 given in the FD&C Act. The EUA policy empowers the Commissioner of FDA to allow and authorize usage of a medical product(s) which are currently unapproved or an application of an approved medical product which is unapproved by the FDA at the time of a declared emergency in the U.S. with a threat to the public, US military forces or national security. Improved preparedness of public health systems by creating and sustaining investments in technology, skilled people and materials with a strong support from government and public and private sectors will sustain market size.
Biodefense Market, By Product
Anthrax contributed 31.5% to the overall market share in 2015, with target size slated to exceed USD 4.2 billion by 2023. Bacillus anthracis is recognized to be of highest priority in biodefense research, and placed among the nine agents in class A as per the classification by CDC. This was followed by smallpox, which is now eradicated worldwide following the global immunization process. The last reported case through natural transmission was in Somalia in 1977. By 1986 all the member countries of WHO were free from smallpox. The U.S. government has allocated more than USD 50 billion since 2001 for prevention from overall biological threats.
Various activities organized by U.S. government bodies such as BioShield legislation, Joint Program Executive Office-Chemical and Biological Defenses (JPEO-CBD) and Biomedical Advanced Research and Development Authority (BARDA) provide sufficient funds and dosage of vaccines against anthrax. The viral hemorrhagic and radiation segments are expected to register higher CAGRs during the forecast timeframe. Rapid rise in research and development investments as a result of Ebola outbreaks and the possibility involving the virus being used as a bio-weapon should drive growth.
Biodefense Market, By Region
North America contributed the largest regional share, with USD 8.9 billion in 2015. U.S. biodefense market share dominated North American revenue, which can be attributed to the increasing government initiatives, funding for biodefense, and implementation of Project BioShield in 2004 with an objective of research fund allocation across the federal agencies.
With the rising saturation in the North American industry, Europe market is being eyed upon as the most lucrative segment and is set to witness the highest CAGR of 11.4% during the forecast period. In 2012, USD 75.66 million in funds was directed towards initiatives involving civilian and military research programs by United Kingdom’s Ministry of Defense.
The government of Japan came up with new National Defense Program Guidelines (NDPG) in December 2010 aimed at guiding Japan's defense policy in the foreseeable future, and help Japan deal with changing security environment including North Korea's rising threat of missile and nuclear systems, and China's rising influence across the globe.
Biodefense Market, By Competitive Market Share
Global biodefense industry is relatively less competitive due to specialized nature of the products, and low commercial demand of the products. However, key players compete to gain access to defense contracts. There are very few local and regional players due to high entry barriers. Incumbent players thrive by implementing merger and acquisition strategy in order to maintain leadership position. The major players include Xoma Corporation, Emergent Biosolutions, PharmaAthene, Bavarian-Nordic, SIGA Technologies, and Cleveland BioLabs, etc.
With virtue of its Russian subsidiary Incuron, LLC, Cleveland BioLabs entered into a three-year research contract with Ministry of Industry and Trade of Russian Federation in 2013 for development of CBLB 502 Entolimod in a deal valued at USD 4.6 million.
Biodefense Industry Background
The biodefense market share is highly influenced by the government initiatives in response to the rising threat of biological, chemical as well as nuclear terrorism. The industry is also witnessing a healthy funding scenario for the R&D activities. The developing and underdeveloped countries should be looked upon as future revenue generators, after Europe owing to industry maturity in the U.S. These countries have high unmet needs. For instance, lack of appropriate infrastructure and R&D facilities in the underdeveloped African countries significantly worsened the situation involving Ebola outbreaks. Industry experts suggest that collaborative efforts between the governments of the U.S. and these countries will enable players to cater to the untapped opportunities in these regions.
What Information does this report contain?
Why Global Market Insights?Comprehensive Research
- All-inclusive coverage
- In-depth and granular data (ex: information for 8 to 15 countries, with clients open to add to this list, in each report)
- Penetrative insights & latest trends
- Offers holistic understanding of the market
- Unique methodology
- Iterative in nature to eliminate errors
- Detailed methodology, scope, assumptions and data sources available for reference
- Committed to making a positive difference for our clients
- Given the nature of this industry, we are committed to ensure that our clients get maximum return on their investment in our services
- Every purchase comes with an option to obtain additional information:
- up to 10% of the original cost
- 45-minute analyst tele-call to obtain further clarity on the market.
- Global Market Insights, Inc. strictly adheres to PCI-DSS security norms.
- Only PCI-DSS compliant payment methods used for highest level of client data security